Nalaganje...
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
BACKGROUND: Phase 3 trials have shown that nintedanib reduces the decline in forced vital capacity (FVC) in patients with mild-to-moderate idiopathic pulmonary fibrosis (IPF) with acceptable safety profiles; however, its effects on advanced IPF are unclear. We investigated the efficacy and safety of...
Shranjeno v:
| izdano v: | Respir Res |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2018
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6194688/ https://ncbi.nlm.nih.gov/pubmed/30340638 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-018-0907-8 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|